Maintenance therapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced lung cancer (either squamous non-small cell or small cell) that has not spread beyond the chest and is not curable with surgery or radiation.
- You must have completed four cycles of standard first-line treatment (immunotherapy plus chemotherapy) and your cancer has not progressed.
- You must be in generally good health, able to take care of yourself (ECOG performance status 0 or 1).
- Your last dose of first-line treatment must have been within 28 days of starting this trial.
- You must have adequate organ function and no serious immune-related side effects from previous immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy drug (nab-paclitaxel) combined with local treatments like radiation for small cell lung cancer that has come back after previous treatment. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests two immunotherapy drugs (sacituzumab govitecan with atezolizumab or durvalumab) as ongoing treatment to keep extensive-stage small cell lung cancer from progressing. It is for people who have already completed initial chemotherapy and immunotherapy without their cancer getting worse.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This trial tests a new combination treatment for people with advanced non-small cell or small cell lung cancer that cannot be removed by surgery or cured with standard treatments. It aims to see if the combination is safe and effective.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.